Trevi Therapeutics, Inc. (TRVI): Total Liabilities
$10.20M
As of 2025-12-31
$9.01M
As of 2026-06-30
-13.1%
3-year compound annual growth
-12.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.20M | -9.4% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $11.26M | +64.2% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $6.86M | -55.9% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $15.56M | -27.3% | 2024-03-20, Balance as of period end |
| 2021-12-31 | $21.40M | +7.8% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $19.85M | n/a | 2022-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | 2025-12-31 | $10.20M | -9.4% |
| Adicet Bio, Inc. (ACET) | 2025-12-31 | $33.15M | -1.4% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $306.60M | -7.0% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $305.93M | +3.9% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $33.55M | +28.6% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $5.61M | +144.2% |
| COMPASS Pathways plc (CMPS) | 2025-12-31 | $263.20M | +346.3% |
Compare TRVI, ACET, FHTX, URGN side by side · Screen every company in Pharmaceutical Preparations ↗